Immunogenicity of Twinrix in older adults: a critical analysis.
Twinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) is the first combined vaccine to provide protection against both hepatitis A and B. This review presents a critical analysis of antibody responses stratified by age following vaccination with Twinrix in 264 adults aged above 40 years. A month after completion of a 0-, 1-, 6-month vaccination schedule with Twinrix, a good response was observed for both anti-HAV and anti-HBs serum antibodies, suggesting that is an effective vaccine in older adults.
Stoffel
Michel
M
GlaxoSmithKline Biologicals, Rixensart, Belgium. michel.stoffel@gskbio.com
Lievens
Marc
M
Dieussaert
Ilse
I
Martin
Isabelle
I
André
Francis
F
D000328:Adult; D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic; D015897:Comorbidity; D016208:Databases, Factual; D005260:Female; D035922:Hepatitis A Antibodies / Q000096:biosynthesis / Q000097:blood; D022362:Hepatitis A Vaccines / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D014611:Vaccination; D017778:Vaccines, Combined / Q000276:immunology*
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; C433226:twinrix